What we do
The EIF in 2020
Coronavirus: The EIB Group’s initiatives to address its economic consequences
Pan-European Guarantee Fund – EGF
Institutional investors
Equity products
AI Co-Investment Facility
Climate & Infrastructure Funds
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
ESCALAR Programme
Debt products
New ESIF ERDF Guarantee Fund initiative in Greece
EFSI Private Credit Programme
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
Skills & Education Guarantee Pilot
EREM debt products
Single EU Debt Financial Instrument
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
EaSI Funded Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Fons d’Inversió en Tecnologia Avançada (FITA) Catalonia
Dutch Future Fund (DFF)
Dutch Alternative Credit Instrument (DACI)
PORTUGAL BLUE: a new initiative for blue economy investments
JEREMIE Greece Reflows – Business Angels’ Co-Investment Equity Instrument
German Corona Matching Facility (CMF)
Portugal Growth programme
Croatian Growth Investment Programme (CROGIP)
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund 1 (BIF 1)
Baltic Innovation Fund 2 (BIF 2)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Competitiveness Fund-of-Funds for SMEs in Romania
The Cyprus Entrepreneurship Fund (CYPEF)
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
ESIF Fund-of-Funds Greece
EAFRD FoF Portugal
EAFRD FoF Romania
The ERP-EIF Facility
ERP-EIF Co-Investment Growth Facility
The LfA-EIF Facilities
The German Future Fund (GFF) - EIF Growth Facility
INAF – French National Agricultural Initiative
ESIF Energy Efficiency and Renewable Energy Malta
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
InvestBG Equity Instrument
Romania Recovery Equity Fund of Funds
JEREMIE Romania Reflows – Equity Instrument
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Portugal Venture Capital Initiative (PVCi)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)
EAFRD FoF Greece
Irish Innovation Seed Fund (IISF)

Clariness: boosting clinical trials


Clariness is about bringing medical innovations to market faster by accelerating clinical trials. Founded in 2005, the company has always focussed on bringing together big data and the field of healthcare.

“Clinical trials require a certain number of patients for efficiency and safety. They’re an integral part of commercialising a new drug, and the longer it takes to get the product to the market, the less patent time a drug will have. Competition is fierce. Every day could cost a million euros – literally. Our platform can help speed up clinical trials by 3-8 months,” explains co-founder and CEO Michael Stadler. “And there’s also obviously a health dimension in terms of making available new, effective drugs to patients in need. We have a passion for digital solutions, but I don’t think we could have set up a data-driven business in the field of debt collection!”

Clariness runs ClinLife, a free and easy-to-use website that helps patients worldwide find the most relevant clinical studies suitable to their medical condition. “There are many patients out there with conditions that have no cure,” says Michael. “Anything from migraines to rare diseases or cancer. Maybe 40% of patients can find some sort of benefit from medication. The rest are looking for improvements. So what our platform does is match trials conducted by pharmaceutical companies with patients looking for cure. Sometimes I say it’s a bit like booking.com, but for clinical trials.

Clariness can offer help with the preparation of clinical studies, finding the patients, retaining them and offering patients insights based on live data. “We wanted to introduce more transparency, clarity and openness into the clinical trials space, increasing awareness among patients, with public data and easy access.” The company’s name actually comes from clarity and openness…”

With up to 42 million visits annually, across 50 countries and 35 languages, the company is on a growth trajectory. In mid-2019, Clariness attracted interest and received an equity investment from Rocket Internet Capital Partners, a venture-capital firm backed by the EIF under the EU’s Investment Plan for Europe. The investment helped the company develop the product further and open an office in China.

“As we generate more and more patient data, we want to look into feeding it back into pharmaceutical companies, to help develop drugs and design trials in a better way,” says Michael. Clariness could play an important role in helping to overcome the coronavirus pandemic: “We’ve already had a first request for trials for a Covid-19 vaccine and we expect this to start in the summer. If all goes well, and the candidate is the right one, we might have a vaccine available sometime next year.”

Company: Clariness (Germany)

Type of business: healthcare

EU-supported finance: RCR and own resources; ERP, EFSI sub-window 1

Financial Intermediary: Rocket Internet Capital Partners

For further information about EIF intermediaries in Germany, please refer to: http://www.eif.org/what_we_do/where/de


We use cookies to give the best browser experience on our website. or change cookie settings.

Note: Following the recent withdrawal of the United Kingdom from the European Union, we are updating the relevant EIF.org pages.


Copyright ©

 European Investment Fund   – The European Investment Fund is not responsible for the content of external internet sites.